8/29/2025

Janusmed amning

Janusmed amning – okrelizumab

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Okrelizumab

Okrelizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Anderson A, Jacobs D, LaHue SC, et al. Ocrelizumab in postpartum women with multiple sclerosis: Low transfer into breast milk and reassuring infant development in a multicenter cohort. actrims 2022 Forum:Session PS2 Abstract P413. 2022.

  2. Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R et al. Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Ann Clin Transl Neurol. 2023;10(11):2053-2064.

  3. Laura Witt, Sandra Thiel, Ralf Gold, and Kerstin Hellwig. Child Development After Exposure to Monoclonal Antibodies During Breastfeeding (S7003). Neurology.

  4. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723.

  5. Chey SY, Kermode AG. Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis. Mult Scler J Exp Transl Clin. 2022;8(1):20552173221085737.

  6. Schwake C, Steinle J, Thiel S, Timmesfeld N, Haben S, Ayzenberg I et al. Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200264.

  7. Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C et al. Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200349.

  8. Oreja-Guevara C, Wray S, Buffels R, Zecevic D, Vukusic S. Pregnancy outcomes in patients treated with ocrelizumab. ECTRIMS Online Library. Poster. 2019

  1. Anderson A, Jacobs D, LaHue SC, et al. Ocrelizumab in postpartum women with multiple sclerosis: Low transfer into breast milk and reassuring infant development in a multicenter cohort. actrims 2022 Forum:Session PS2 Abstract P413. 2022.
  2. Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R et al. Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Ann Clin Transl Neurol. 2023;10(11):2053-2064.
  3. Laura Witt, Sandra Thiel, Ralf Gold, and Kerstin Hellwig. Child Development After Exposure to Monoclonal Antibodies During Breastfeeding (S7003). Neurology.
  4. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723.
  5. Chey SY, Kermode AG. Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis. Mult Scler J Exp Transl Clin. 2022;8(1):20552173221085737.
  6. Schwake C, Steinle J, Thiel S, Timmesfeld N, Haben S, Ayzenberg I et al. Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200264.
  7. Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C et al. Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200349.
  8. Oreja-Guevara C, Wray S, Buffels R, Zecevic D, Vukusic S. Pregnancy outcomes in patients treated with ocrelizumab. ECTRIMS Online Library. Poster. 2019

Innehållet senast uppdaterat 8/13/2025